It was announced by Aimmune on August 31, 2020 that it had signed an agreement to be acquired by SNP for approximately $2.6 billion. Aimmune stockholders will receive $34.50 in cash for each share of Aimmune common stock owned, pursuant to the merger agreement. The deal is scheduled to be closed in the fourth quarter of 2020.
It is alleged in the complaint that Aimmune’s board of directors oversaw an unfair process and ultimately agreed to a merger agreement that was inadequate. Aimmune stock has recently traded at a price well above the merger consideration of $34.50.
Aimmune Therapeutics, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to email@example.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at firstname.lastname@example.org.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
1800 Century Park East, Suite 600
Los Angeles, CA 90067